Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine.

Aim of the study is to assess the optimal dosage and safety in this setting.
Breast Cancer
DRUG: Gemcitabine|DRUG: docetaxel
Time to treatment failure (TTTF), baseline to stopping treatment
Response rate, baseline to measured progressive disease|Duration of response, time of response to progressive disease|Overall survival, baseline to date of death from any cause|Time to progressive disease, baseline to measured progressive disease
Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine.

Aim of the study is to assess the optimal dosage and safety in this setting.